This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Use of Simvastatin as a Steroid Sparing Agent for ...
Clinical trial

Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

Read time: 1 mins
Last updated:8th Sep 2014

The trial will compare the effect on disease control and immunosuppression treatment of adding simvastatin 80mg once daily, over a follow-up and treatment period of 2 years. Patients will be randomised in a 1:1 fashion to standard treatment with placebo or standard treatment with the addition of simvastatin (80mg daily). They will be followed at 3 months intervals for 2 years with a primary end point of mean reduction in corticosteroid dosage at the 12 month follow-up visit.

Category Value
Study start date 2014-09-08

View full details